PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer

Background Increasing evidence has indicated that several B7 family members play critical roles in the progress of many cancers. However, the clinical significance of the B7 family in cutaneous squamous cell carcinoma (cSCC) is still elusive. The purpose of this study is to investigate the potential role of B7-H1 biomolecules (PD-L1) in regulating the tumorigenesis and progression of cSCC, the most common non-melanoma skin cancer. Methods We collected transcriptome data of cSCC patients from TCGA databases (n = 496) and subjected the transcription data to bioinformatical analysis. Differential expression of B7-H1 genes with a grade-dependent pattern was identified. We collected paraffin sections of skin squamous carcinoma and analyzed by immunohistochemical staining. We further examined the PD-L1 levels of CD14+ cells in peripheral blood of each cSCC patient and normal subjects by flow cytometry. Results It was found that higher expression of PD-L1 was associated with poor prognosis of cSCC patients and shorter overall survival. These observations were further verified in the clinical paraffin sections and in peripheral blood T cells. Conclusion Our study reveals that PD-L1 is a potential prognostic marker in clinical prognosis for cSCC patients and could be valuable for cSCC treatment.

[1]  M. Lacouture,et al.  CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies. , 2020, Journal of the American Academy of Dermatology.

[2]  A. Lokki,et al.  Eculizumab Treatment for Postpartum HELLP Syndrome and aHUS—Case Report , 2020, Frontiers in Immunology.

[3]  E. Gagari,et al.  Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? , 2019, Current opinion in oncology.

[4]  E. Hui Immune checkpoint inhibitors , 2019, Reactions Weekly.

[5]  M. Zhou,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[6]  A. Wrona Role of immunotherapy in stage III nonsmall cell lung cancer , 2019, Current opinion in oncology.

[7]  Haibo Yu,et al.  Indoleamine 2, 3-dioxygenase and B7-H1 expressions as prognostic and follow-up markers in human pancreatic carcinoma. , 2018, Pathology, research and practice.

[8]  A. Hauschild,et al.  PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.

[9]  Q. Du,et al.  B7‐H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma , 2018, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  S. Paydaş,et al.  PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus , 2018, Journal of Clinical Pathology.

[11]  C. Schmults,et al.  Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. , 2018, Journal of the American Academy of Dermatology.

[12]  J. Dai,et al.  Association between B7-H1 and cervical cancer: B7-H1 impairs the immune response in human cervical cancer cells , 2017, Experimental and therapeutic medicine.

[13]  A. Iyer,et al.  PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..

[14]  G. Pupo,et al.  PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors , 2017, Clinical Cancer Research.

[15]  M. Mohammadi,et al.  RETRACTED ARTICLE: Prognostic investigations of B7-H1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma , 2015, Tumor Biology.

[16]  E. Wherry,et al.  Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.

[17]  Jingting Jiang,et al.  Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance , 2015, International Journal of Clinical Oncology.

[18]  Rui Zhang,et al.  B7-H1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3(+) regulatory T-cell infiltration. , 2014, Acta histochemica.

[19]  G. Esendagli,et al.  T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands , 2014, Breast Cancer Research and Treatment.

[20]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[21]  H. V. van Boven,et al.  Overall survival and PD‐L1 expression in metastasized malignant melanoma , 2011, Cancer.

[22]  M. Caligiuri,et al.  The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. , 2010, Blood.

[23]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Xiaomei Wang,et al.  B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. , 2009, Neuro-oncology.

[25]  J. Schlesselman,et al.  Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Allison,et al.  BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 , 2003, Nature Immunology.

[27]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[28]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[29]  S. Dzik B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[30]  G. Zhu,et al.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.